compound introduction
(S)-ML753286 is a breast cancer resistance protein ( BCRP ) inhibitor with an IC 50 of 0.6 μM on BCRP efflux transporter. In Vivo (S)-ML753286 (Compound A) shows the potency and a potent pharmacokinetic (PK) profile in rats (lower clearance [1.54 L/h/kg] and higher bioavailability [123%]). XL388 has moderate terminal elimination half-life with t 1/2 s of 0.9 h and 2.0 h for 2 mg/kg (iv) and 20 mg/kg (po) in rats, respectively . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:IC50: 0.6 μM (BCRP efflux transporter)
